GlassScriptPhysician profile
Fred B Sammons
NPI 1114338647
$4,708.77
in general payments reported to CMS, 2019-2025
37 companies · $528 in 2025
The $528 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $480 · 2020: $627 · 2021: $973 · 2022: $796 · 2023: $696 · 2024: $608 · 2025: $528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,833.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,832.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,112.54 | 2019-2025 | |
| Novo Nordisk INC | $646.65 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $436.29 | 2021-2025 | Vraylar, Qulipta |
| Lilly USA, LLC | $396.99 | 2019-2025 | Jardiance, Mounjaro, Trulicity |
| Amgen INC. | $246.19 | 2019-2025 | Repatha, Otezla, Repatha |
| Esperion Therapeutics, INC. | $225.22 | 2021 | |
| Janssen Pharmaceuticals, INC | $210.01 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.89 | 2019-2024 | Jardiance, Ofev |
| Eisai INC. | $138.36 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $135.66 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $125.85 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $125.13 | 2019 | |
| Xeris Pharmaceuticals, INC. | $101.72 | 2022-2024 | Gvoke Hypopen, Keveyis |
| Astellas Pharma US INC | $83.36 | 2019-2022 | |
| Portola Pharmaceuticals, LLC | $57.27 | 2019 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fred Sammons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.